

The Molecular Evidence Development Consortium (MED-C)

 consortiapedia.fastercures.org/consortia/med-c/

Research Areas



Tool Development

Data Sharing



Biomarker Research

Drug, Genomic Biomarker



Data-Sharing Enabler



Product Development

Data

At a Glance

- Status: **Active Consortium**
- Year Launched: **2015**
- Initiating Organization: **Dr. Dane Dickson**
- Initiator Type: **Nonprofit foundation**
- Location: **North America**

Abstract

MED-C is a response to the lack of collaboration between key stakeholders in health care that is holding back progress in the promising domain of personalized medicine. Each of these groups wants what's best for patient care and recognizes the tremendous potential benefits of personalized medicine, but they have not yet been able to develop a unified approach. MED-C is working to change that. Personalized medicine needs data – lots of it. After consulting with leaders in each of medicine's major groups, MED-C is developing a registry of genomic data and clinical outcomes from treatments of patients diagnosed with cancer. This data will be readily accessible to physicians, researchers, pharmaceutical companies, regulators, and insurance companies.

Mission

Medical care will become more accurate and precise, time and resources will be better used, money

will be put to better use, and more lives will be saved. MED-C seeks to personalize medicine.

Consortium History

In early 2015, Dr. Dane Dickson, an oncologist from Idaho, saw the need for a new approach to personalized medicine. He built a collaborative product from the ground up that would fix the most pressing issues of patient disconnect the nation was facing. This product was the MED-C consortium.

Financing

MED-C seeks partnerships, sponsorships and financial support to help them more quickly build an infrastructure that will advance molecular medicine. They welcome donations.

Intellectual Property

The data that is collected by this initiative will be widely available for research by all groups, who working together, can achieve new milestones in cancer treatment

Patent Engagement

MED-C encourages patient engagement as one of the six key groups that must work together to advance personalized medicine.

Impact/Accomplishment



To view MED-C in the news and their accomplishments, click [here](#)

Links/Social Media Feed

Homepage <http://med-c.org/>

Points of Contact

Molecular Evidence Development Consortium
1800 M Street N.W., Suite 1050
Washington DC 20036

Phone: (202) 800-0611

Sponsors & Partners

Genentech
Eli Lilly
Illumina
Thermo Fisher Scientific
Celgene

Updated: **06/21/2017**